WCG
DMK

Weaver Consulting Group’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Weaver Consulting Group’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-32
Closed -$2K – 966
2020
Q3 		$2K Hold
32
– – ﹤0.01% 856
2020
Q2 		$1K Hold
32
– – ﹤0.01% 923
2020
Q1 		$1K Buy
+32
New +$1.36K ﹤0.01% 827

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RW
RVW Wealth Los Angeles, California $1.52B AUM 23.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Weaver Consulting Group's DMK Position: Q4 2020 in Review

Weaver Consulting Group sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2020, closing a stake of 32 shares — an estimated $2K sold.

Weaver Consulting Group first reported a position in DMK in Q1 2020 and held it in 3 quarters. The position peaked at $2K in Q3 2020. 41 funds tracked by Wall St. Rank hold DMK as of Q4 2020.

  • Weaver Consulting Group reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2020 after selling out during the quarter.
  • Weaver Consulting Group sold 32 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2020, an estimated $2K.
  • Weaver Consulting Group first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q1 2020 and held it in 3 quarters.
  • Weaver Consulting Group's DMK Pharmaceuticals Corporation Common Stock position peaked at $2K in Q3 2020.
  • 41 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2020.

Based on Weaver Consulting Group's 13F filing for Q4 2020, filed 29 Jan 2021.